FHFahim Hilal

Fahim Hilal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fahim Hilal has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In vivo systemic toxicity assessment of Bacillus safensis NMCC-189: a probiotic strain evaluated via short-term tolerability and 28-day repeated-dose (OECD 407) study in Balb/c mice

    by Maryam Khan Sherwani, Syeda Rida Zainab, Jehan Zeb Khan, Shakira Ghazanfar, Fahim Hilal, Rimsha Noor, Muhammad Khalid Tipu

    Live biotherapeutic products are emerging as supports for host physiology and gastrointestinal health. However, despite their broad use and apparent safety, the in vivo toxicity of new probiotic strains must be rigorously evaluated before human application. Bacillus safensis NMCC-189, a spore-forming bacterium with promising probiotic potential, was assessed through a 14-day short-term repeated-dose tolerability study to confirm initial safety followed by sub-acute (28-day) oral toxicity study conducted in accordance with Organisation for Economic Co-operation and Development (OECD) test guideline 407. Male and female Balb/c mice were orally administered low (1 × 108 CFU/mL) and high doses (1 × 1010 CFU/mL) of B. safensis NMCC-189 corresponding to approximately 1 × 109 CFU/kg/day 1 × 1011 CFU/kg/day. Dose selection was based on established probiotic safety ranges and toxicological principles. Clinical signs, survival, body weight, food intake, haematology, serum biochemistry, organ weights, and histopathology were examined, alongside daily in-life monitoring, randomisation, and blinding. No morbidity, mortality, or treatment related clinical abnormalities were observed in either study phase. Body weight gain, food consumption, and behavioural patterns remained within normal physiological limits. Haematological and biochemical parameters showed no toxicologically relevant changes, and minor fluctuations remained within reference ranges. Gross and microscopic examination of major organs revealed no pathological changes. The no observed adverse effect level (NOAEL) was 1 × 1011 CFU/kg/day. These findings suggest that B. safensis is well tolerated following oral administration and support its safety as a probiotic candidate. Overall, the combined study design provided a structured framework for the preclinical toxicological assessment of live biotherapeutic products.

  • Therapeutic efficacy of Bacillus clausii via NFκB/Nrf-2/HO-1 pathway modulation in a CFA-induced arthritis model

    by Fahim Hilal, Jehan Zeb Khan, Muhammad Usama Mazhar, Syeda Rida Zainab, Jawad Azam, Gulrukh Latif, Nadeem Irshad, Fawad Ali Shah, Muhammad Khalid Tipu

  • Pretreatment with probiotics (Bacillus safensis NMCC-189 and Bacillus clausii) prevents epileptogenesis in mice via modulation of BBB integrity, oxidative stress, and neurotransmitter balance

    by Maryam Khan Sherwani, Jehan Zeb Khan, Shakira Ghazanfar, Fahim Hilal, Rimsha Noor, Muhammad Khalid Tipu

    Epilepsy remains a difficult neurological condition to treat using conventional therapies. Emerging evidence links gut microbiota to the onset and progression of neurological disorders, including epilepsy. In this study, pretreatment with Bacillus safensis NMCC-189 and Bacillus clausii (probiotics) on epileptogenesis was evaluated. The probiotics were administered orally (108 CFU/ml/day) for 14 days, followed by PTZ administration (60 mg/kg i.p) on day 14. The colon length, biochemical/microbiological analysis of fecal matter with oxidative stress markers, confirmed the colonization of the colon with the bacterium in the mice and improved colon health. The mice supplemented with the probiotics bacteria showed significant anticonvulsant effects via delaying onset, reducing severity and duration of the seizures with no mortality in comparison to the non-supplemented PTZ-kindled mice. Protective action in the supplemented mice can be explained by reduced oxidative stress in the brain tissue. Moreover, RT-PCR results showed that prior administration of Bacillus safensis NMCC-189 and Bacillus clausii successfully restored the expression of tight junction (ZO-1, Occludin, Claudin), and normalized glutamatergic (NR1, NR2A, NR2B, mGluR1, GluA1, GluA2) and GABAergic (GABRA1, GABRB1) gene expression altered by PTZ administration, indicating strong neuroprotective and barrier-preserving effects. These findings highlight the potential of probiotics to mitigate excitotoxicity, restore neurotransmitter balance, and protect epithelial and blood–brain barriers in epilepsy. This study highlights Bacillus safensis NMCC-189 and Bacillus clausii as promising probiotics that modulate gut microbiota and exhibit neuroprotective effects, targeting key mechanisms of epileptogenesis. Furthermore, being part of microbial flora, these probiotics lack any side effects, unlike traditional anti-epileptic drugs.


  • Bacillus subtilis (NMCC-path-14) ameliorates acute phase of arthritis via modulating NF-κB and Nrf-2 signaling in mice model

    by Muhammad Usama Mazhar, Sadaf Naz, Tayyaba Zulfiqar, Jehan Zeb Khan, Fahim Hilal, Shakira Ghazanfar, Muhammad Khalid Tipu

    Probiotics (PBT) have been extensively studied as an adjunct therapy for various inflammatory conditions. This is because inflammation often leads to dysbiosis, a microbial imbalance that can be corrected using PBT. Most research has focused on Lactobacillus, with limited data on Bacillus PBT for alleviating CFA-induced arthritis in animal models. While most studies focus on the chronic aspect of CFA-induced arthritis, our current research aims to evaluate the effects of pre-treatment, concurrent treatment, and post-treatment with Bacillus subtilis (NMCC-path-14) against the acute phase of arthritis induced by CFA in the mice model. Arthritis was produced by administering CFA into the subplantar region of the mouse’s right hind paw. Pain-related behavioral parameters, antioxidant capacity, histological and radiological parameters, expression of essential cytokines, and DNA damage were assessed during the acute phase. B. subtilis treatment significantly reduced the paw edema and improved the arthritic index. The nocifensive threshold was also raised, and muscle coordination improved considerably after B. subtilis treatment on days 7 and 14. The antioxidant capacity and histological and radiological parameters were also enhanced. We demonstrated that B. subtilis therapy preserved the DNA during the acute phase of arthritis using the Comet assay. Comparing results to the arthritic control, a significant reduction was observed in the expression levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and nuclear factor-kappa B (NF-κB). In contrast, the level of nuclear factor erythroid 2-related factor 2 (Nrf-2) was enhanced. During the acute phase of the disease, B. subtilis displayed a potent anti-inflammatory and anti-arthritic action against CFA-induced arthritis.